Setting the stage for an extraordinary one-day meeting of the Vaccines and Related Biological Products Advisory Committee this Thursday, the FDA has cleared 2 experts of financial conflicts to help beef up the committee. And regulators went on to specify the safety, efficacy and CMC input they’re looking for on EUAs, before they move on to the full BLA approval process.
All of this has already been spelled out to the developers. But the devil is in the details, and it’s clear from the first round of posted responses that some of the top players — including J&J and Pfizer — would like some adjustments and added feedback. And on Thursday, the experts can offer their own thoughts on shaping the first OKs.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 92,500+ biopharma pros reading Endpoints daily — and it's free.
Business - Latest - Google News
October 26, 2020 at 05:34PM
https://ift.tt/37GDPcE
Bayer buys a biotech 'race horse' with a $4B deal — $2B in cash — aimed at going big into gene therapy - Endpoints News
Business - Latest - Google News
https://ift.tt/2Rx7A4Y
Bagikan Berita Ini
0 Response to "Bayer buys a biotech 'race horse' with a $4B deal — $2B in cash — aimed at going big into gene therapy - Endpoints News"
Post a Comment